How High Will Airbnb Stock Go?
Airbnb, Inc. (NASDAQ:ABNB) share price has seen substantial turbulence over…
Sell
35
HLOSF Quote, Financials, Valuation and Earnings
Last price:
$1.35
Seasonality move
:
-23.39%
Day range:
$1.35 - $1.35
52-week range:
$0.93 - $1.73
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
32.00x
P/B ratio:
6.04x
Volume:
--
Avg. volume:
315
1-year change:
-14.83%
Market cap:
$121.7M
Revenue:
$862.4K
EPS (TTM):
-$0.47
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HLOSF
Healios KK
|
-- | -- | -- | -- | -- |
|
AMGXF
AnGes
|
-- | -- | -- | -- | -- |
|
PPTDF
PeptiDream
|
-- | -- | -- | -- | -- |
|
SNBIF
SanBio
|
-- | -- | -- | -- | -- |
|
SOLTF
Nxera Pharma
|
-- | -- | -- | -- | -- |
|
TAK
Takeda Pharmaceutical
|
$7.2B | -- | 0.1% | -- | $16.03 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HLOSF
Healios KK
|
$1.35 | -- | $121.7M | -- | $0.00 | 0% | 32.00x |
|
AMGXF
AnGes
|
$0.36 | -- | $86.6M | -- | $0.00 | 0% | 22.98x |
|
PPTDF
PeptiDream
|
$17.15 | -- | $2.2B | 20.38x | $0.00 | 0% | 7.14x |
|
SNBIF
SanBio
|
$4.65 | -- | $329.8M | -- | $0.00 | 0% | 78.05x |
|
SOLTF
Nxera Pharma
|
$6.16 | -- | $553.6M | -- | $0.00 | 0% | 2.79x |
|
TAK
Takeda Pharmaceutical
|
$13.17 | $16.03 | $41.8B | 21.79x | $0.33 | 4.7% | 1.39x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HLOSF
Healios KK
|
65.07% | -0.707 | 34.39% | 1.33x |
|
AMGXF
AnGes
|
-- | 2.635 | -- | 1.10x |
|
PPTDF
PeptiDream
|
25.75% | -2.667 | 6.45% | 3.28x |
|
SNBIF
SanBio
|
-- | -0.161 | -- | -- |
|
SOLTF
Nxera Pharma
|
48.92% | 1.984 | 55.24% | 3.73x |
|
TAK
Takeda Pharmaceutical
|
42.19% | 0.312 | 78.44% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HLOSF
Healios KK
|
$2.8M | -$1.8M | -55.94% | -137.21% | -24.5% | -$4.8M |
|
AMGXF
AnGes
|
$259.5K | -$13M | -37.32% | -22.74% | -1559.14% | -- |
|
PPTDF
PeptiDream
|
$17.4M | -$854.5K | 24.02% | 34.66% | -1.5% | $173.8M |
|
SNBIF
SanBio
|
-- | -$6.2M | -- | -- | -- | -$10.9M |
|
SOLTF
Nxera Pharma
|
$48.9M | $5.4M | -2.75% | -5.58% | 11.44% | $10.3M |
|
TAK
Takeda Pharmaceutical
|
$5.3B | $1.8B | 2.37% | 4.01% | 15.97% | $1.3B |
Healios KK vs. Competitors
-
Which has Higher Returns HLOSF or AMGXF?
AnGes has a net margin of -107.23% compared to Healios KK's net margin of -2947.39%. Healios KK's return on equity of -137.21% beat AnGes's return on equity of -22.74%.
Company Gross Margin Earnings Per Share Invested Capital HLOSFHealios KK86.35% -$0.04 $57.8M AMGXFAnGes31.07% -$0.11 $158.3M -
What do Analysts Say About HLOSF or AMGXF?
Healios KK has a consensus price target of --, signalling downside risk potential of --. On the other hand AnGes has an analysts' consensus of -- which suggests that it could fall by --. Given that Healios KK has higher upside potential than AnGes, analysts believe Healios KK is more attractive than AnGes.
Company Buy Ratings Hold Ratings Sell Ratings HLOSFHealios KK0 0 0 AMGXFAnGes0 0 0 -
Is HLOSF or AMGXF More Risky?
Healios KK has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AnGes has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HLOSF or AMGXF?
Healios KK has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AnGes offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Healios KK pays -- of its earnings as a dividend. AnGes pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HLOSF or AMGXF?
Healios KK quarterly revenues are $3.2M, which are larger than AnGes quarterly revenues of $835.2K. Healios KK's net income of -$3.4M is higher than AnGes's net income of -$24.6M. Notably, Healios KK's price-to-earnings ratio is -- while AnGes's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Healios KK is 32.00x versus 22.98x for AnGes. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HLOSFHealios KK32.00x -- $3.2M -$3.4M AMGXFAnGes22.98x -- $835.2K -$24.6M
-
Which has Higher Returns HLOSF or PPTDF?
PeptiDream has a net margin of -107.23% compared to Healios KK's net margin of -5.57%. Healios KK's return on equity of -137.21% beat PeptiDream's return on equity of 34.66%.
Company Gross Margin Earnings Per Share Invested Capital HLOSFHealios KK86.35% -$0.04 $57.8M PPTDFPeptiDream47.13% -$0.02 $551.4M -
What do Analysts Say About HLOSF or PPTDF?
Healios KK has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream has an analysts' consensus of -- which suggests that it could fall by --. Given that Healios KK has higher upside potential than PeptiDream, analysts believe Healios KK is more attractive than PeptiDream.
Company Buy Ratings Hold Ratings Sell Ratings HLOSFHealios KK0 0 0 PPTDFPeptiDream0 0 0 -
Is HLOSF or PPTDF More Risky?
Healios KK has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PeptiDream has a beta of 0.826, suggesting its less volatile than the S&P 500 by 17.389%.
-
Which is a Better Dividend Stock HLOSF or PPTDF?
Healios KK has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PeptiDream offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Healios KK pays -- of its earnings as a dividend. PeptiDream pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HLOSF or PPTDF?
Healios KK quarterly revenues are $3.2M, which are smaller than PeptiDream quarterly revenues of $36.8M. Healios KK's net income of -$3.4M is lower than PeptiDream's net income of -$2.1M. Notably, Healios KK's price-to-earnings ratio is -- while PeptiDream's PE ratio is 20.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Healios KK is 32.00x versus 7.14x for PeptiDream. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HLOSFHealios KK32.00x -- $3.2M -$3.4M PPTDFPeptiDream7.14x 20.38x $36.8M -$2.1M
-
Which has Higher Returns HLOSF or SNBIF?
SanBio has a net margin of -107.23% compared to Healios KK's net margin of --. Healios KK's return on equity of -137.21% beat SanBio's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HLOSFHealios KK86.35% -$0.04 $57.8M SNBIFSanBio-- -$0.08 -- -
What do Analysts Say About HLOSF or SNBIF?
Healios KK has a consensus price target of --, signalling downside risk potential of --. On the other hand SanBio has an analysts' consensus of -- which suggests that it could fall by --. Given that Healios KK has higher upside potential than SanBio, analysts believe Healios KK is more attractive than SanBio.
Company Buy Ratings Hold Ratings Sell Ratings HLOSFHealios KK0 0 0 SNBIFSanBio0 0 0 -
Is HLOSF or SNBIF More Risky?
Healios KK has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison SanBio has a beta of -0.336, suggesting its less volatile than the S&P 500 by 133.637%.
-
Which is a Better Dividend Stock HLOSF or SNBIF?
Healios KK has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SanBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Healios KK pays -- of its earnings as a dividend. SanBio pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HLOSF or SNBIF?
Healios KK quarterly revenues are $3.2M, which are larger than SanBio quarterly revenues of --. Healios KK's net income of -$3.4M is higher than SanBio's net income of -$5.8M. Notably, Healios KK's price-to-earnings ratio is -- while SanBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Healios KK is 32.00x versus 78.05x for SanBio. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HLOSFHealios KK32.00x -- $3.2M -$3.4M SNBIFSanBio78.05x -- -- -$5.8M
-
Which has Higher Returns HLOSF or SOLTF?
Nxera Pharma has a net margin of -107.23% compared to Healios KK's net margin of 12.96%. Healios KK's return on equity of -137.21% beat Nxera Pharma's return on equity of -5.58%.
Company Gross Margin Earnings Per Share Invested Capital HLOSFHealios KK86.35% -$0.04 $57.8M SOLTFNxera Pharma78.44% $0.09 $928.9M -
What do Analysts Say About HLOSF or SOLTF?
Healios KK has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Healios KK has higher upside potential than Nxera Pharma, analysts believe Healios KK is more attractive than Nxera Pharma.
Company Buy Ratings Hold Ratings Sell Ratings HLOSFHealios KK0 0 0 SOLTFNxera Pharma0 0 0 -
Is HLOSF or SOLTF More Risky?
Healios KK has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nxera Pharma has a beta of 0.337, suggesting its less volatile than the S&P 500 by 66.345%.
-
Which is a Better Dividend Stock HLOSF or SOLTF?
Healios KK has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nxera Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Healios KK pays -- of its earnings as a dividend. Nxera Pharma pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HLOSF or SOLTF?
Healios KK quarterly revenues are $3.2M, which are smaller than Nxera Pharma quarterly revenues of $62.4M. Healios KK's net income of -$3.4M is lower than Nxera Pharma's net income of $8.1M. Notably, Healios KK's price-to-earnings ratio is -- while Nxera Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Healios KK is 32.00x versus 2.79x for Nxera Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HLOSFHealios KK32.00x -- $3.2M -$3.4M SOLTFNxera Pharma2.79x -- $62.4M $8.1M
-
Which has Higher Returns HLOSF or TAK?
Takeda Pharmaceutical has a net margin of -107.23% compared to Healios KK's net margin of 7.83%. Healios KK's return on equity of -137.21% beat Takeda Pharmaceutical's return on equity of 4.01%.
Company Gross Margin Earnings Per Share Invested Capital HLOSFHealios KK86.35% -$0.04 $57.8M TAKTakeda Pharmaceutical66.47% $0.19 $83.8B -
What do Analysts Say About HLOSF or TAK?
Healios KK has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical has an analysts' consensus of $16.03 which suggests that it could grow by 20.8%. Given that Takeda Pharmaceutical has higher upside potential than Healios KK, analysts believe Takeda Pharmaceutical is more attractive than Healios KK.
Company Buy Ratings Hold Ratings Sell Ratings HLOSFHealios KK0 0 0 TAKTakeda Pharmaceutical3 1 0 -
Is HLOSF or TAK More Risky?
Healios KK has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Takeda Pharmaceutical has a beta of 0.498, suggesting its less volatile than the S&P 500 by 50.209%.
-
Which is a Better Dividend Stock HLOSF or TAK?
Healios KK has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Takeda Pharmaceutical offers a yield of 4.7% to investors and pays a quarterly dividend of $0.33 per share. Healios KK pays -- of its earnings as a dividend. Takeda Pharmaceutical pays out 199.34% of its earnings as a dividend.
-
Which has Better Financial Ratios HLOSF or TAK?
Healios KK quarterly revenues are $3.2M, which are smaller than Takeda Pharmaceutical quarterly revenues of $7.9B. Healios KK's net income of -$3.4M is lower than Takeda Pharmaceutical's net income of $619.7M. Notably, Healios KK's price-to-earnings ratio is -- while Takeda Pharmaceutical's PE ratio is 21.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Healios KK is 32.00x versus 1.39x for Takeda Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HLOSFHealios KK32.00x -- $3.2M -$3.4M TAKTakeda Pharmaceutical1.39x 21.79x $7.9B $619.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
60
QMCO alert for Dec 26
Quantum [QMCO] is up 49.62% over the past day.
Buy
53
ARQQ alert for Dec 26
Arqit Quantum [ARQQ] is up 49.85% over the past day.
Buy
65
TSLL alert for Dec 26
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 3.73% over the past day.
